Page 3 of 294: studies 21 to 30 of 2,936, newest first. Back to the psychedelic-assisted therapy overview
OSF Preprints September 10, 2026 Bartosz Helfer, Katarzyna Henke‐Ciążyńska, Daniel Pankowski et al. preprint
The original data comprise the extraction, coding, identity mappings and appraisals produced for the accompanying meta-research study. Their source material is previously published literature.
The International Journal of Neuropsychopharmacology September 9, 2026 Katarzyna Henke‐Ciążyńska, Daniel Pankowski, Bartosz Helfer
Abstract Background Systematic reviews with meta-analyses (SR-MAs) of psychedelic-assisted psychotherapy (PAP) guide clinical and policy decisions. Their trustworthiness depends, in part, on how consistently different SR-MAs assess risk of bias (RoB) in the same underlying randomized controlled trials (RCTs), and how transparently those judgments are justified. Aims & Objectives To summarise...
The International Journal of Neuropsychopharmacology September 9, 2026 David Erritzøe
Abstract Background Recent clinical and neuroscientific work has revived interest in psychedelic-assisted therapies as promising treatments for a range of psychiatric conditions. Mechanistically, classical psychedelics and atypical agents such as ketamine appear to act as catalysts of neural and psychological flexibility, disrupting entrenched patterns of activity in “stuck” brain networks and...
Journal of Psychopharmacology September 7, 2026 Torsten Passie, Michiel van Elk
Common wisdom in the psychedelic literature suggests that early controlled trials of psychedelic therapy were methodologically flawed. In this review we challenge this view and discuss 11 controlled studies that were conducted in the United States and Canada between 1965 and 1977 to evaluate psychedelic (peak) therapy for individuals suffering from alcohol and opioid use disorder and...
Current Addiction Reports September 2, 2026 Kathryn Fletcher, Jack Freestone, Nadine Ezard et al.
Abstract Purpose of Review Psychedelic-assisted therapy (PAT) has re-emerged as a potential intervention for substance use disorders (SUDs), yet the psychological mechanisms underlying behaviour change remain poorly synthesised. This scoping review mapped and evaluated proposed psychological processes underpinning PAT in adults with SUDs. Recent Findings Peer-reviewed English-language empirical...
Psychoanalytic Inquiry August 28, 2026 Diana Moga
Autistic individuals are more susceptible to trauma due to higher baseline anxiety and overwhelm; poorer episodic memory; and the frequent lack of a sense of community, safety, and belonging that are both protective and needed to heal from trauma. Furthermore, many autistic adults have adopted a false self to get by in a neurotypical world and are often cut off from their affective, embodied...
The American journal of hospice & palliative care August 28, 2026 Krishna Hanubal, Akul Munjal, Jino Park et al.
PurposeDespite most psychedelic substances remaining Schedule I, clinical research exploring psychedelic-assisted therapy (PAT) in oncology is expanding. We sought to assess oncology providers' attitudes toward and understanding of PAT.MethodsWe conducted a cross-sectional survey of healthcare professionals involved in oncology across five academic institutions in California, South Carolina,...
Psychopharmacology August 27, 2026 Frederick S. Barrett, David Wolinsky, Zach Daily et al.
RATIONALE: Delta-9-tetrahydrocannabinol (Δ9-THC) has been reported to evoke psychedelic-like experiences at high doses in some individuals. However, the doses of Δ9-THC that occasion such effects and the phenomenology of these experiences are poorly understood. OBJECTIVES: This brief report presents preliminary findings from a pilot human laboratory study that directly compared the acute...
Progress in Neuro-Psychopharmacology and Biological Psychiatry August 20, 2026 Charalampos L. Kandilakis, Costas Papatheodoropoulos
Psychedelic-assisted therapy has emerged as a promising therapeutic approach across several psychiatric disorders, yet the mechanisms linking acute brain-state changes and subjective experience to sustained clinical improvement remain incompletely understood. Here, we extend a previously proposed excitation/inhibition (E/I)-centred dual-phase model of psychedelic action to the therapeutic...
Journal of Psychopharmacology August 17, 2026 Lana Strika-Bruneau, Chérine Elhssaini, Baptiste Fauvel et al.
Background: Psychedelic-assisted psychotherapy (PAP) shows promise for substance use disorders (SUDs), yet the respective contributions of pharmacological, experiential, psychotherapeutic, and contextual factors remain insufficiently understood. Objective: To synthesize contemporary clinical evidence on PAP for SUDs, with particular attention to therapeutic frameworks, dosing strategies,...